Compare the evidence
Danaher vs Repligen vs Sartorius
Compare bioprocess purification tools, consumables and process validation. Product workflows differ; company-wide economics are not a measurement of validated batch throughput or AI-specific revenue.
Read horizontally within each row. Product ratings, planned capacity, completed deliveries and current financials describe different stages.
On narrow screens, scroll the comparison horizontally. Each figure keeps its period, accounting definition and source. GAAP cash flow, adjusted margins, segment gross profit and EBITDA are not interchangeable.
| Research dimension | DanaherDHR · Checked 2026-10-21 | RepligenRGEN · Checked 2026-10-21 | SartoriusSRT · Checked 2026-10-21 |
|---|---|---|---|
| Industrial role | Bioprocessing equipment and consumables through Cytiva | Filtration, chromatography and process analytics | Chromatography systems and single-use bioprocess tools |
| Constraint to test | Validated biological purification workflows and consumable continuity | Validated downstream purification and fluid-management throughput | Validated purification, resin utilization and scalable process control |
| Reported evidence and sources | Danaher identifies Cytiva, including the Pall Life Sciences business, within its biotechnology portfolio.
| Repligen describes filtration systems, pre-packed chromatography columns, fluid management and process analytics for biologics.
| Sartorius offers batch, continuous and preparative chromatography systems for biopharmaceutical processing.
|
| Capacity and delivery |
|
|
|
| Reported economics | Not quantified in this profile. | ||
| Evidence coverage | Primary-source operating or segment results; capacity evidence retains its stated stage. Constraint-specific revenue, pricing power and valuation are not quantified. Product relevance does not establish pure-play exposure. No quantified share of revenue attributable to the specific constraint. No evidence-strength score is assigned. | Primary-source operating or segment results; capacity evidence retains its stated stage. Constraint-specific revenue, pricing power and valuation are not quantified. Product relevance does not establish pure-play exposure. No quantified share of revenue attributable to the specific constraint. No evidence-strength score is assigned. | Public product or operations profile. Quantitative economic exposure has not been reviewed here. Constraint-specific revenue, pricing power and valuation are not quantified. Product relevance does not establish pure-play exposure. No quantified share of revenue attributable to the specific constraint. No evidence-strength score is assigned. |
| Counter-evidence | No separately sourced counter-evidence review is included in this baseline. The conditions below are research tests. | No separately sourced counter-evidence review is included in this baseline. The conditions below are research tests. | No separately sourced counter-evidence review is included in this baseline. The conditions below are research tests. |
| Next to monitor |
|
|
|
| What would weaken the case? |
|
|
|
Open in Excel or another spreadsheet. Each entry preserves its source, date and accounting definition; research interpretations are labeled.
How to use this comparison
Start with the constraint, inspect the dated sources, then follow the company to monitor new evidence. A documented industrial role does not establish a shortage or an attractive share price.
This comparison uses open company research checked on the dates shown. Valuation and expected returns require a separate review.